Beta

    fda approve gedatolisib for advanced breast cancer

    Before Jul 1, 2026

    fda approve gedatolisib for advanced breast cancer. Best Yes near 18¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 18¢ · Best No: 85¢ · 1 platform

    • Kalshi: Yes 18¢ / No 85¢
    LIVE

    Before Jul 1, 2026

    Volume

    $2.5K

    $3 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Jul 1, 2026

    ~15 days left

    Category

    Culture

    18¢CHANCE OF YES17%83%
    Yes
    18¢
    Kalshi
    No
    85¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    KalshiKalshi
    Best Yes
    Best No
    Yes
    18¢
    No
    85¢
    Vol
    $2.5K
    $3 24h
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Jul 1, 2026, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 18¢: exit costs ~1.03¢/contract
    Full calculator

    Market Details

    ResolutionResolves Jul 1, 2026
    Time Left15 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In